RANDALL C. WILLIS. Through bioprospecting, new drugs may be just an ocean away.
|
|
- Clinton Sherman
- 6 years ago
- Views:
Transcription
1 January 2002 Vol. 5, No. 1, pp Focus: Automation Feature Article Table of Contents MDD Home Contact Us Sitemap Nature s pharma sea RANDALL C. WILLIS Through bioprospecting, new drugs may be just an ocean away. For millions of years, humans and their anthropological predecessors harvested natural products for their medicinal qualities the bark of a specific tree to alleviate pain or the gland of a fish for its hallucinogenic effect in an effort that is now called bioprospecting. But as analytical technologies advanced in the last century and scientists got a firmer grasp on the medicinally active components of many natural products, we began to turn away from natural sources. In the past 100 years, organic chemistry largely replaced bioprospecting, and the advents of combinatorial chemistry and in vitro assays have increased throughput to the point that the pharmaceutical industry now pumps out dozens of new products each year. But most of these new drugs are based on small chemical changes to existing drugs; and of the thousands, perhaps millions, of chemical shapes available to pharmaceutical researchers, only a few hundred are being explored. What compounds are being missed? In combinatorial chemistry, people felt that we could generate a lot of new structures and we could screen much more rapidly, says Jay Short, president and CEO of San Diego s Diversa Corp. The problem is that whereas natural products have a function in the environment, combinatorial chemistry has no functional filter. These molecules are randomly generated and synthesized. Page 1 of 5
2 You had to search through many more molecules to find those ones with a function, Short continues. That, I think, is why combinatorial chemistry has not delivered what it was originally sold as delivering, even though it clearly has delivered in terms of the area of optimizing molecules. Computational biology has picked up some of the pharmacological slack, as exemplified by the SHAPES library developed at Vertex Pharmaceuticals; but even these attempts have rested on what was already in the database ( 1). And, as described in 2001: A dock odyssey ( Modern Drug Discovery, September 2001, pp 26 32), in silico drug design is still in its infancy and many think that our technological grasp outreaches our intellectual base. What else is available to us? Where should we go for new leads, or how should we reexamine the old ones? Diversity is strength When researchers first looked in earnest for biologically active substances in marine products, they were surprised by the chemical diversity not only among the products but also between them and compounds isolated from terrestrial sources. This chemical novelty was likely due to the nature of the environment in which the molecules evolved saltwater, which provided a rich source of halogens. But beyond the chemical diversity, the sea also provided amazing biological diversity. If you look at the fundamental phyla of life, there are 34; and 17 occur on land, whereas 32 occur in the sea [with some overlap], says William Fenical, researcher at the Scripps Institute of Oceanography (La Jolla, CA) and co-founder of Nereus Pharmaceuticals (San Diego). From the fundamental point of view of biodiversity, the ocean is far more diverse and really would have been the best place to start to develop a natural pharmacy. People developed an interest in convincing the pharmaceutical industry that they ought to begin to look at submarine sources because of this very high chemical diversity, Fenical continues. It was a total failure, because there were already things happening with respect to synthetic chemistry and combinatorial chemistry. The people that run these companies are so far extended from marine systems that they felt uncomfortable doing it. No one ever chose to invest the resources time and financial resources that they had done in the last 30 years on terrestrial systems. The era of computer-assisted design, combinatorial chemistry, and parallel chemistry began to evolve such that natural product work, especially over the past 10 years, became less of a focal point of big pharma. A couple of companies dabbled, as Fenical describes it, and found things, but they never made a commitment, leaving the field open to smaller companies (see box, Small fish with big plans ). In all fairness, he admits, natural product research is difficult for big pharma because it is by nature slower than combinatorial chemistry and there was a move to higher throughput. Page 2 of 5
3 When you take a combinatorial pathway, you start with a molecule that has a couple of requirements, says Fenical. The compound must have groups that can be functionalized carbon-carbon bonds are rarely formed and you need to start with a scaffold with inherent biological activity. For example, paclitaxel, an anticancer drug marketed as Taxol that was derived from the Pacific yew tree, was a revelation, according to Fenical, in that it did some things that never could have been predicted. It has a mechanism of action that no one could have designed an assay to discover. Breeding an antibody Octopus s garden Not quite as dramatic an event as the discovery of Taxol was the work of Werner Bergmann. In the early 1950s, Bergmann and his colleagues isolated thymine and uridine pentofuranosides from air-dried sponges, calling the two compounds spongothymidine and spongouridine, respectively ( 2, 3). Before the discovery of these biologically active nonribose or deoxyribose nucleosides, chemists in search of improved antibiotics had concentrated their efforts on modifying the base moieties. Now, there was an interest in making changes to the sugars. With the recognition that the sugar moiety could be modified while still maintaining biological activity, wrote Stringner Yang and his colleagues at the National Cancer Institute (NCI) in a recent review ( 4), a significant number of nucleosides were made with regular bases but modified sugars, or both acyclic and cyclic derivatives, including AZT and ultimately acyclovir. The same work, according to Alejandro Mayer, a researcher at Midwestern University (Downers Grove, IL), led to the synthesis of arabinosyl cytosine, an anticancer agent that is produced by Pharmacia under the brand name Cytosar-U ( 5). But this work was the exception to the rule, as the conventional pharmaceutical industry still concentrated its efforts on synthetic and combinatorial chemistries. Marine biology remained a largely untapped source of compounds until the NCI started a discovery initiative in the 1970s, which led to the discovery of a dozen or so products (e.g., bryostatin 1 and dolastatin 10) that just now are reaching or have recently started clinical trials ( Table 1). Most marine bioprospecting has focused on an eclectic menagerie of invertebrate organisms sponges, tunicates, mollusks, and sea hares, to name a few ( 6). And a quick survey of the literature suggests that most of the active products being tested are toxins, typically used as part of a defense mechanism. On a coral reef, what you have is chemical warfare, said the NCI s David Newman in a recent interview. Every invertebrate needs to have a toehold on the reef so it can feed, and the way to defend that toehold is to develop a more powerful poison sac than the competition. The watery milieu of these organisms also helps account for the potency Page 3 of 5
4 of their toxins. Surrounded by so much water, the toxins are rapidly diluted and therefore must act quickly. An example of just such a toxin is ziconotide, a compound being developed by Elan Pharmaceuticals that is derived from a cone snail. But whereas the snail uses the chemical to poison its prey, Elan hopes to use it to treat chronic pain. It would be wrong, however, to assume that all of the biologically active compounds being tested are toxins. Because there is almost no money available for antibiotic or anti-inflammatory drug discovery, says Fenical, the people who are out there exploring have grants from the NCI and by definition are using cytotoxicity end points. It is grossly inaccurate to say that the ocean, therefore, is composed of those molecules. We see a broad cross section of diverse structure types that appear to have biological activities across the board. Marine microbes Although much of the early research on marine natural products focused on organisms such as sponges, tunicates, and mollusks, the sources that have garnered attention recently are marine bacteria and fungi. There is even suspicion that some of the biologically active compounds isolated from the larger organisms may in fact have been products of symbiotic microorganisms. According to Fenical, as you move away from the continents, the sea chemistry changes, and this is reflected in the microbiology. As you go north, the waters become colder; and the microbes have adapted to deal with the temperature. As you move down from the surface, oxygen levels decrease, light diminishes, and pressure increases. Each of these changes is matched by the organisms, resulting in an incredible diversity one that almost approaches an alien environment. What was really surprising, says Short, was the relatively low homology or sequence identity across species and an exceptionally low relatedness to other genes. The scientific literature of the past 100 years has documented and described perhaps 10,000 microbial species, according to Short, whereas the genomics approach taken by Diversa suggests that this number will shortly increase 200-fold, bringing with it new biologically active molecules. Many of these proteins have entirely different catalytic mechanisms than anything that you ve seen in eubacteria, says Short. That s really what has allowed our enzyme area to take off and why we have such a rich pipeline. And as William Fenical says, The ocean is the last frontier of natural products research, whether big pharma gets into it or not. References Page 4 of 5
5 1. Bemis, G. W.; Murcko, M. A. J. Med. Chem. 1996, 39, Bergmann, W.; Feeney, R. J. J. Am. Chem. Soc. 1950, 72, Bergmann, W.; Feeney, R. J. J. Org. Chem. 1951, 16, Yang, S. S.; et al. J. Nat. Prod. 2001, 64, Mayer, A. M. S. Pharmacologist 1999, 41, Schwartsmann, G.; et al. Lancet Oncol. 2001, 2, Randall C. Willis is an assistant editor of Modern Drug Discovery. Send your comments or questions about this article to or the Editorial Office by fax at or by post at th Street, NW; Washington, DC Return to Top Table of Contents Copyright 2002 American Chemical Society Page 5 of 5
Potencial de los productos naturales marinos como agentes anticáncer: La situación de Panamá
RIBECACER Potencial de los productos naturales marinos como agentes anticáncer: La situación de Panamá VIII Simposio Iberoamericano de plantas medicinales y III Simposio Iberoamericano de investigación
More informationMarine Genetic Resources: Experiences in Commercialization. Background
Marine Genetic Resources: Experiences in Commercialization Marc Slattery University of Mississippi, and ational Institute for Undersea Science & Technology cean Biotechnology Center & Repository United
More informationIntroduction to Drug Design and Discovery
Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,
More informationDrug Discovery Toxicology Webinar
1 2012 2013 Vertex Pharmaceuticals Incorporated Drug Discovery Toxicology Webinar Brandon Jeffy, Ph.D., DABT Toxicologist, Discovery and Investigative Fellow Vertex Pharmaceuticals, San Diego Site 05 APR
More informationPharmaceutical Drugs. Chemistry 199L. (Chapter 19)
Pharmaceutical Drugs Chemistry 199L Pharmaceutical Drugs (Chapter 19) Pain relievers and fever reducer: aspirin (Sunblock) (Aspirin) 1827 1893 Stomach distress Few & bleeding side-effect Analgesic (pain
More informationMarineinspired Oncology
Marineinspired Oncology Nature distributed medicine everywhere. Pliny the Elder. 74 AD 2 3 Leaders in marine biotecnology Group structure Oncology Company Other business PharmaMar is a global biopharmaceutical
More informationMadagascar periwinkle (Catharanthus roseus) Salix - willow. Biodiversity: Use it or lose it. Biodiversity: Use it or lose it
Applying basic ecological science to make a difference Human Impact on Earth s Ecosystems ~50% of land surface and accessible fresh water used by humans C increase is leading to climate change H H H H
More informationCase Study: Dr. Jonny Wray, Head of Discovery Informatics at e-therapeutics PLC
Reaxys DRUG DISCOVERY & DEVELOPMENT Case Study: Dr. Jonny Wray, Head of Discovery Informatics at e-therapeutics PLC Clean compound and bioactivity data are essential to successful modeling of the impact
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationPharmaMar A Biopharmaceutical Company
From Marine Expeditions to New Drugs in Oncology 26 June, 2007 Contents PharmaMar A Biopharmaceutical Company BioDiversity: The Business Case The Current Research Environment Value Creation: The R&D Process
More information1-Microbial Taxonomy: classification nomenclature identification
Part 1 Basic Medical Microbiology 1-Microbial Taxonomy: Taxonomy is the area of biologic science comprising three distinct, but highly interrelated, disciplines that include classification, nomenclature,
More informationAbout Clinical Trials: What They Can Mean For You?
About Clinical Trials: What They Can Mean For You? Karl Cremer, PharmD and AnnKatrin Petersen, MD, MS January 25, 2012 ClinicalStudy.org Owned and operated by PRI, Inc. 5927 Balfour Court, Suite 201 Carlsbad,
More informationSoil bacteria to produce new antibiotics
Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/soil-bacteria-to-produce-newantibiotics/ Soil bacteria to produce new antibiotics An ever-growing number of genomes of
More informationMarineinspired Oncology
Marineinspired Oncology Nature distributed medicine everywhere. Pliny the Elder. 74 AD 2 3 Leaders in marine biotecnology Group structure Oncology Company Other business PharmaMar is a global biopharmaceutical
More informationReal World Drug Discovery A Chemist's Guide to Biotech and Pharmaceutical Research
Real World Drug Discovery A Chemist's Guide to Biotech and Pharmaceutical Research Robert M. Rydzewski ELSEVIER Amsterdam Boston Heidelberg London New York Oxford Paris San Diego San Francisco Singapore
More informationThe Integrated Biomedical Sciences Graduate Program
The Integrated Biomedical Sciences Graduate Program at the university of notre dame Cutting-edge biomedical research and training that transcends traditional departmental and disciplinary boundaries to
More informationMARINE NATURAL PRODUCTS BIOTECHNOLOGY. Russell T. Hill University of Maryland Biotechnology Institute, Baltimore, Maryland, USA
MARINE NATURAL PRODUCTS BIOTECHNOLOGY Russell T. Hill University of Maryland Biotechnology Institute, Baltimore, Maryland, USA Keywords: marine, natural products, biomedical, biotechnology, drug discovery,
More informationGenetics Lecture 21 Recombinant DNA
Genetics Lecture 21 Recombinant DNA Recombinant DNA In 1971, a paper published by Kathleen Danna and Daniel Nathans marked the beginning of the recombinant DNA era. The paper described the isolation of
More informationThe Need for Scientific. Data Annotation. Alick K Law, Ph.D., M.B.A. Marketing Manager IBM Life Sciences.
The Need for Scientific Data Annotation Alick K Law, Ph.D., M.B.A. Marketing Manager IBM Life Sciences alaw@us.ibm.com Cross disciplinary research approach requires organizations to address diverse needs
More information... And how about another QUIZ!!! The Environment: What s It Worth? 4/25/11
4/25/11... And how about another QUIZ!!! The Environment: What s It Worth? 1. A species that holds an ecosystem together is a. 2. Life forms that carry out photosynthesis would be known as in a food web.
More informationBusiness and Industry Advisory Committee to the OECD - Comité Consultatif Economique et Industriel Auprès de l OCDE
Business and Industry Advisory Committee to the OECD - Comité Consultatif Economique et Industriel Auprès de l OCDE In Committee BIOTECHNOLOGY: A KEY CONTRIBUTOR TO SUSTAINABLE ECONOMIC GROWTH A Vision
More informationAPPLIED BLUE BIOTECHNOLOGY MASTER
Applied Blue Biotechnology Master 1/7 APPLIED BLUE BIOTECHNOLOGY MASTER IDENTITY CARD Domain : Sciences, Technologies and Health Initial training Continuing training Degree apprenticeships 60 ECTS credits
More informationUnited Nations Open-ended Informal Consultative Process on Oceans and the Law of the Sea June 25-29, 2007, UN HQ New York
United Nations Open-ended Informal Consultative Process on Oceans and the Law of the Sea June 25-29, 2007, UN HQ New York Jamaica s marine genetic resources: challenges and opportunities Marcia Creary
More informationBIO8041 BIO3030. Antimicrobial Drug Discovery
BIO8041 BIO3030 Antimicrobial Drug Discovery Module overview Intended Knowledge Outcomes The aim of this module is to demonstrate various routes to the discovery of microbial products with commercial value.
More informationAndrew Schorr: Is there anything you ve been discussing that you d like to update people about now?
News from ASH: Advances in Bleeding Disorders ASH Conference Coverage December 8, 2008 Craig Kessler, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors,
More informationMeet the CEO developing the Next Generation of Antibody Therapeutics
Meet the CEO developing the Next Generation of Antibody Therapeutics Written by Evelyn Warner Editor in Chief, Labiotech.eu Crescendo Biologics has positioned itself as the successor of Cambridge Antibody
More informationQuo vadis Drug Discovery
Quo vadis Drug Discovery Donatella Verbanac, Dubravko Jelić, Sanja Koštrun, Višnja Stepanić, Dinko Žiher PLIVA - Research Institute, Ltd. Prilaz baruna Filipovića 29, 10000 Zagreb, CROATIA The Pharmaceutical
More informationChapter 10 Microbial Genetics: New Genes for Old Germs
Chapter 10 Microbial Genetics: New Genes for Old Germs Objectives: After reading Chapter Ten, you should understand The structure and complexity of the bacterial chromosome and the significance of plasmids.
More informationMagellan Bioscience Business and Capabilities. Applications of Marine Microorganisms. Overview of Collection and Process Development
Overview Magellan Bioscience Business and Capabilities Applications of Marine Microorganisms Overview of Collection and Process Development Magellan BioScience Group, Inc. Location: Tampa, Florida Founded:
More informationPharmaceutical Informatics and the Pathway to Personalized Medicines
Pharmaceutical Informatics and the Pathway to Personalized Medicines Sangtae Kim and Venkat Venkatasubramanian Purdue University ICCS2007 DDDAS Workshop Beijing May 26-28, 2007 Outline The Grand Challenge
More informationCEOCFO Magazine. Dr. Jakub Staszak-Jirkovsky Co-Founder and Chief Executive Officer. Machavert Pharmaceuticals
CEOCFO Magazine ceocfointerviews.com All rights reserved Issue: February 11, 2019 Developing the first Drug Candidates based on Phospholipid that Activates Natural Killer Cells, Machavert Pharmaceuticals
More informationApplied Blue Biotechnology Master
Applied Blue Biotechnology Master 1/8 Applied Blue Biotechnology Master Field : Sciences, Technologies, Santé Initial training Continuing training Block/release program 60 ECTS credits 2 semesters Course
More informationProtein Synthesis: From Gene RNA Protein Trait
Protein Synthesis: From Gene RNA Protein Trait Human Genome The human genome contains about genes. Each gene is a of DNA (sequence of nitrogen bases) contained within each chromosome. Each chromosome contains
More informationPharmaceuticals and Biotechnology
ABCD Pharmaceuticals and yet are quickly accessible from one central location. 7 Gain a competitive advantage 7 Facilitate product research and development 7 Raise return on investment Pharmaceuticals
More informationIs the grass greener on the other side.? Academia to Industry Stephen B. Helliwell
Is the grass greener on the other side.? Academia to Industry Stephen B. Helliwell Senior Investigator, Novartis Institutes for BioMedical Research Is the grass greener? http://eatrio.net/2013/04/portuguese-idioms-joao-sem-braco.html
More informationIntegration of FDSS7000 into a modular robotic system for Open Innovation drug discovery
Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery José Manuel Brea & María Isabel Loza BioFarma, Santiago de Compostela DRUG DISCOVERY OPEN INNOVATION CLOSED innovation
More informationBy Memorie Yasuda DID YOU EVER WONDER
F O R K I D S O F A L L A G E S By Memorie Yasuda 34 DID YOU EVER WONDER what makes you different from your best friend? Why does she have brown eyes and you have blue? And maybe in a silly moment, you
More informationSolution Story: Beating the competition to market in drug development
Elsevier s R&D Solutions DRUG DISCOVERY & DEVELOPMENT Solution Story: Beating the competition to market in drug development Reset Therapeutics leverages the interoperability of Elsevier s R&D Solutions
More informationPractice Exam A. Briefly describe how IL-25 treatment might be able to help this responder subgroup of liver cancer patients.
Practice Exam 2007 1. A special JAK-STAT signaling system (JAK5-STAT5) was recently identified in which a gene called TS5 becomes selectively transcribed and expressed in the liver upon induction by a
More informationThe era of biological medicines
Chapter 1 The era of biological medicines Since their first use in the 1980s, biological medicines (including biosimilar medicines) have grown to become an indispensable tool in modern medicine. Worldwide,
More informationLesson Overview. Studying the Human Genome. Lesson Overview Studying the Human Genome
Lesson Overview 14.3 Studying the Human Genome THINK ABOUT IT Just a few decades ago, computers were gigantic machines found only in laboratories and universities. Today, many of us carry small, powerful
More informationMeet the iseq 100 System.
Meet your new lab partner our smallest, most accessible, and affordable next-generation sequencing (NGS) solution ever. Want deeper biological insights, better experimental efficiency, and greater discovery
More informationCellular Assays. A Strategic Market Analysis. Sample Slides
A Strategic Market Analysis Sample Slides 2002 For information contact: Frontline Strategic Consulting, Inc. 1065 E. Hillsdale Blvd, Suite 403, Foster City, CA 94404 650-525-1500 x125, x135 or x145 info@frontlinesmc.com
More informationCalifornia Current Ecosystem Plankton Food Web
What role do plankton play in the food web? : California Current Ecosystem Plankton Food Web and the Beth Simmons Education and Outreach Coordinator, CCE LTER, Scripps Institution of Oceanography, and
More informationRecent years have witnessed an expansion in the disciplines encompassing drug
Course overview Recent years have witnessed an expansion in the disciplines encompassing drug discovery outside the pharmaceutical industry. This is most notable with a significant number of Universities
More informationHierS Hierarchical Scaffold- Based Molecular Clustering
HierS Hierarchical Scaffold- Based Molecular Clustering Steven J. Wilkens Genomics Institute of the Novartis Research Foundation GNF Founded in 1999 Over 400 employees Located in Torrey Pines Research
More informationBiotech Patents in Europe
Biotech Patents in Europe Introduction This circular relates to biotech patent practice in Europe. It is based on our experience of drafting and prosecuting biotech applications. The circular is written
More informationTHE UNIVERSITY OF THE WEST INDIES CAVE HILL CAMPUS
THE UNIVERSITY OF THE WEST INDIES CAVE HILL CAMPUS Undergraduate Studies in the Department of Biological and Chemical Sciences EARTH SCIENCES BIOLOGY ECOLOGY MICROBIOLOGY CHEMISTRY BIOCHEMISTRY Earth Sciences
More informationBasic Information. I.1 If your company performs biotechnology research and development, uses a. The Categories of Biotechnology Applications.
APPENDIX 2 SURVEY QUESTIONNAIRE Part I. Basic Information I.1 If your company performs biotechnology research and development, uses a biotechnology process in manufacturing, or produces research tools,
More informationStudying the Human Genome. Lesson Overview. Lesson Overview Studying the Human Genome
Lesson Overview 14.3 Studying the Human Genome THINK ABOUT IT Just a few decades ago, computers were gigantic machines found only in laboratories and universities. Today, many of us carry small, powerful
More informationFrom Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase
An Executive Summary From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase Leveraging knowledge about an API s physicochemical properties
More informationThe main goal of the strategic partnership is the development of innovative, all-natural cosmetic active ingredients and aroma molecules.
PRESS RELEASE Symrise: Strategic partnership with BRAIN and AnalytiCon Discovery (Holzminden/Potsdam/Zwingenberg, April 2, 2007) Symrise GmbH & Co. KG, the world s fourth-largest supplier of fragrance
More informationPresentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development
Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationComputational Drug Design
Computational Drug Design Univ.-Prof. Dr. Gerhard F. Ecker Pharmacoinformatics Research Group Department of Medicinal Chemistry, University of Vienna Althanstrasse 14, A-1090 Wien, Austria e-mail: gerhard.f.ecker@univie.ac.at;
More informationBiotechnology: Unlocking Nature s Secrets
Course Syllabus Biotechnology: Unlocking Nature s Secrets Course Code: EDL052 Course Description How is technology changing the way we live? Is it possible nature can provide all the answers to some of
More informationMARINE FUNGI Understanding the biology of marine fungi for the production of secondary metabolites to establish a natural product library
MARINE FUNGI Understanding the biology of marine fungi for the production of secondary metabolites to establish a natural product library Dr. Antje Labes Helmholtz Center for Ocean Research Kiel Marine
More informationLIVING ENVIRONMENT Mid-term Review Part 1 Name: Period:
LIVING ENVIRONMENT Mid-term Review Part 1 Name: Period: Part One: Diagrams 1. What concept is represented in the diagram below? ecological succession 2. A) Identify 2 producers from the diagram: Eucalyptus
More informationCalifornia Current Ecosystem Plankton Food Web
TEACHER PAGES What role do plankton play in the food web? California Current Ecosystem Plankton Food Web and the Beth Simmons Education and Outreach Coordinator, CCE LTER, Scripps Institution of Oceanography,
More informationESOF2010,Torino 2-7 July
1 From Life Science to Environmental Science: Successes and Challenges Teresa Lettieri European Commission Joint Research Centre; Institute for Environment and Sustainability http://ies.jrc.ec.europa.eu/
More informationMICROBIAL BIOPROSPECTING
MICROBIAL BIOPROSPECTING MICROBIAL BIOPROSPECTING Brazil, due to its large diversity of biomes and ecosystems, its large territorial extension, and its location between the tropics, where the planet s
More informationUnit 2 RELEVANCE OF ECOLOGY TO MARINE ECOTOURISM DEVELOPMENT
Unit 2 RELEVANCE OF ECOLOGY TO MARINE ECOTOURISM DEVELOPMENT Objectives At the completion of this unit, you will be able to: Understand the fundamentals of coral reef ecology Identify threats to reef health
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationBioprocess Knowledge Is Power
Bioprocess Knowledge Is Power www.themedicinemaker.com 3 Best Practice Bioprocess Knowledge Is Power Outsourcing can be an effective way to access indepth bioprocessing expertise, but leaning on external
More informationAlternative CRISPR system could improve genome editing
Alternative CRISPR system could improve genome editing Smaller enzyme may make process simpler and more exact. Heidi Ledford 25 September 2015 Justin Knight Photography Synthetic biologist Feng Zhang is
More informationEnergy Biosciences Institute Linking Biotechnology and Energy. March 25, 2010 Paul Willems, TVP Energy Biosciences EBI Associate Director
Energy Biosciences Institute Linking Biotechnology and Energy March 25, 2010 Paul Willems, TVP Energy Biosciences EBI Associate Director EBI Partners This Extraordinary partnership builds upon and extends
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationMarin bioprospektering i Trondheimsfjorden. Sergey B. Zotchev Institutt for bioteknologi,, NTNU
Marin bioprospektering i Trondheimsfjorden Sergey B. Zotchev Institutt for bioteknologi,, NTNU Bioprospecting Bioprospecting" was first defined in 1993 as "the exploration of biodiversity for commercially
More informationThe era of biological medicines
Chapter 1 The era of biological medicines Since their first use in the 1980s, biological medicines (including biosimilar medicines) have grown to become an indispensable tool in modern medicine. Worldwide,
More informationDocking Studies of the Binding Mode of Dictyostatin and Its Analogues to the Taxoid Binding Site on Tubulin
Docking Studies of the Binding Mode of Dictyostatin and Its Analogues to the Taxoid Binding Site on Tubulin Christopher B. Hackmeyer Spring Hill College Billy W. Day, Ph.D. Department of Pharmaceutical
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More informationInterview. Maximizing the Value of Biospecimens to Deliver New Therapies. with Clive Green, PhD, Director and Head of Sample Management at AstraZeneca
Interview Maximizing the Value of Biospecimens to Deliver New Therapies with Clive Green, PhD, Director and Head of Sample Management at AstraZeneca Introduction and Background CLIVE GREEN This ebook originated
More informationAntimicrobial Peptides
Antimicrobial Peptides 1 / 6 2 / 6 3 / 6 Antimicrobial Peptides 17 Prediction and Rational Design of Antimicrobial Peptides William F. Porto, Osmar N. Silva and Octávio L. Franco Universidade Católica
More informationINNOVATIVE AND NATURAL ACTIVE MOLECULES FOR HEALTH, NUTRITION AND COSMETICS
INNOVATIVE AND NATURAL ACTIVE MOLECULES FOR HEALTH, NUTRITION AND COSMETICS ANTIFUNGALS COLORING AGENTS ANTIOXIDANTS NUTRITIONAL ADDITIVES ANTIOXIDANTS BIOACTIVE COMPOUNDS PIGMENTS ANTIBIOTICS 1 DEINOVE
More informationLONG-TERM BENEFITS FROM RESEARCH INTO STREPTOMYCES BACTERIA
LONG-TERM BENEFITS FROM RESEARCH INTO STREPTOMYCES BACTERIA Many of the most important antibiotics used in hospitals around the world come from Streptomyces bacteria. Recent discoveries have shown that
More informationOpen-access antimicrobial drug discovery BIO 2016
Open-access antimicrobial drug discovery BIO 2016 Matt Cooper Institute for Molecular Bioscience The University of Queensland Antibiotics are not drug-like Don t obey the rules Rule of Five Molecular Weight:
More informationOpen-access antimicrobial drug discovery BIO 2016
Open-access antimicrobial drug discovery BIO 2016 Matt Cooper Institute for Molecular Bioscience The University of Queensland Antibiotics are not drug-like Don t obey the rules Rule of Five Molecular Weight:
More informationBiology Past and Biology Future: Where have we been and where are we going? IAP, Alexandria December 3, 2006
Biology Past and Biology Future: Where have we been and where are we going? IAP, Alexandria December 3, 2006 Bruce Alberts Professor of Biochemistry and Biophysics University of California, San Francisco
More informationFURTHER EXPLORATIONS ON THE SUBJECT:
FURTHER EXPLORATIONS ON THE SUBJECT: The ocean is one of the earth s final frontiers. We know more about the moon than our oceans. We ve only explored 5% of the ocean, meaning that there is so much more
More informationCOMPUTER AIDED DRUG DESIGN: AN OVERVIEW
Available online on 19.09.2018 at http://jddtonline.info Journal of Drug Delivery and Therapeutics Open Access to Pharmaceutical and Medical Research 2011-18, publisher and licensee JDDT, This is an Open
More informationNATIONAL CENTER FOR CASE STUDY TEACHING IN SCIENCE
Part II Resistance Among the first antibiotics used on a large scale was penicillin, which was discovered in 1929 by Alexander Fleming. It was finally isolated and synthesized in large quantities in 1943.
More informationChromeleon CDS delivers efficiency gains and compliance and data integrity improvements to UK CRO/CMO
CASE STUDY Sterling Pharma Solutions Chromeleon CDS delivers efficiency gains and compliance and data integrity improvements to UK CRO/CMO Brian Alliston is currently a Data Integrity Expert and CDS Specialist
More informationRegulation of enzyme synthesis
Regulation of enzyme synthesis The lac operon is an example of an inducible operon - it is normally off, but when a molecule called an inducer is present, the operon turns on. The trp operon is an example
More informationSchool of Fisheries, Aquaculture and Aquatic Sciences
School of Fisheries, Aquaculture and Aquatic Sciences 1 School of Fisheries, Aquaculture and Aquatic Sciences Fisheries science combines a general foundation in chemistry, mathematics and biological sciences
More informationETHICAL, LEGAL AND SOCIAL ISSUES IN DRUG DEVELOPMENT AND PHARMACOGENOMICS: Report on a Qualitative Study of the Perspectives of Canadian Stakeholders
ETHICAL, LEGAL AND SOCIAL ISSUES IN DRUG DEVELOPMENT AND PHARMACOGENOMICS: Report on a Qualitative Study of the Perspectives of Canadian Stakeholders SHANNON GIBSON University of Toronto Faculty of Law
More informationComplex Adaptive Systems Forum: Transformative CAS Initiatives in Biomedicine
Complex Adaptive Systems Forum: Transformative CAS Initiatives in Biomedicine January 18, 2013 Anna D. Barker, Ph.D. Director, Transformative Healthcare Networks C-Director, Complex Adaptive Systems Initiative
More informationPresidential Commission for the Study of Bioethical Issues 2 nd meeting September
Presidential Commission for the Study of Bioethical Issues 2 nd meeting September 13 14 2010 David B. Weiner, Ph.D. Professor Department of Pathology and Laboratory Medicine University of Pennsylvania
More informationPatenting biotechnological inventions
Patenting biotechnological inventions Izabela Milczarek, PhD, Specialist in Patents Department at Patpol Patpol - European and Polish Patent and Trade Mark Attorneys What is biotechnology? The 20 th century
More informationSupplementing the Immune System with Plant-Produced Antibodies
Supplementing the Immune System with Plant-Produced Antibodies MICH B. HEIN 1 Epicyte Pharmaceutical, Inc. San Diego, CA Antibodies are inherently stable proteins found in all mammals and in fish. They
More informationComputational Drug Discovery
Computational Drug Discovery Guha. January 10, 2006 Two Revolutions Guha. January 10, 2006 A Corpse in the Alps Why interesting? His Possessions Search for Drugs Not New Traditional Chinese medicine and
More informationUsing Computational Chemistry to Identify New Uses for Old Medicines
Using Computational Chemistry to Identify New Uses for Old Medicines http://www.re-pharm.com alan@re-pharm.com Re-Pharm summary > Clinical-stage company actively building a drug development pipeline >
More informationBiotechnology Pathway
Biotechnology Pathway The Biotechnology Systems (BS) Career Pathway encompasses the study of using data and scientific techniques to solve problems concerning living organisms with an emphasis on applications
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationJamaica s marine genetic resources: challenges and opportunities
Jamaica s marine genetic resources: challenges and opportunities Caribbean ABS Workshop Marcia Creary Ford Environmental Data Manager Caribbean Coastal Data Centre Centre for Marine Sciences University
More informationBiotechnology Unit 3: DNA to Proteins. From DNA to RNA
From DNA to RNA Biotechnology Unit 3: DNA to Proteins I. After the discovery of the structure of DNA, the major question remaining was how does the stored in the 4 letter code of DNA direct the and of
More informationOpen Innovation March 2014
Open Innovation March 2014 Open innovation Necessity is the mother of all invention English Proverb ascribed to Plato. Is Open Innovation an idea born out of necessity to survive for big Pharma? Open innovation
More informationProteomics. Manickam Sugumaran. Department of Biology University of Massachusetts Boston, MA 02125
Proteomics Manickam Sugumaran Department of Biology University of Massachusetts Boston, MA 02125 Genomic studies produced more than 75,000 potential gene sequence targets. (The number may be even higher
More informationFOUR SOCIAL MEDIA TACTICS EVERY REAL ESTATE AGENT NEEDS
FOUR SOCIAL MEDIA TACTICS EVERY REAL ESTATE AGENT NEEDS By SAM Rico BATTISTA AWARD WINNING SOCIAL MEDIA EXPERT About this Book First, let s go over what you can expect. This ebook is going to cover the
More informationSuccessful and Faster Drug Development through Data Mining Dirk Belmans, Ph.D. SAS Belgium
Successful and Faster Drug Development through Data Mining Dirk Belmans, Ph.D. SAS Belgium The Life-Cycle of a Successful Pharmaceutical Product Sales Costs Patent Filing R&D time to launch is decreasing
More informationFOLDING CYSTEINE-RICH MINIPROTEINS
Second International Collaborative and Cooperative Chemistry Symposium Program: Tuesday 1 November Lecture Theatre 358; 1.15 pm 2.45 pm FLDING CYSTEINE-RICH MINIPRTEINS Professor Paul Alewood University
More information